Drug intelligence / Profile preview

HEQ-001

Development stage: Preclinical
Lead developer: Heqet Therapeutics
Modality: MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

HEQ-001 is a microRNA-based therapeutic candidate developed by Heqet Therapeutics for the treatment of myocardial infarction. It functions by modulating miR-199a-3p, a non-coding RNA that has been shown to stimulate the proliferation of cardiomyocytes and promote cardiac regeneration. The therapy aims to repair heart tissue damage following a myocardial infarction by activating the heart's endogenous regenerative capacity. Developed in collaboration with King's College London and based on the research of Prof. Mauro Giacca, HEQ-001 is currently in preclinical development and represents a novel approach to restoring heart function by activating endogenous regenerative pathways.

Other names: miR-199a-3pmiR199a-3pmiR 199a-3p

Beyond the preview

Go deeper on HEQ-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEQ-001.

Explore the full profile